JOURNAL ARTICLE

PL2‐AM23‐SN‐30 | Apyrase Reduces Severity of Autoimmune Hemolytic Anemia (AIHA) Secondary to Checkpoint Inhibitors in a Mouse Model.

  • Published In: Transfusion, 2023, v. 63, n. S5. P. 10A 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Zotti, F. Dei; Qiu, A.; Miller, A.; Zimring, J.; Hudson, K. 3 of 3

Abstract

The article focuses on autoimmune hemolytic anemia (AIHA), particularly its increasing incidence as a secondary effect of immune checkpoint inhibitor immunotherapy (ICPi). It highlights the challenges in treating AIHA due to variable success rates and high relapse rates, emphasizing the need for more effective therapies. In a mouse model, treatment with apyrase, which reduces proinflammatory extracellular ATP, significantly improved clinical signs of AIHA by decreasing red blood cell autoantibody levels, inflammation, and anemia. The findings suggest that targeting purinergic signaling may offer a promising new approach for treating AIHA in humans. [Extracted from the article]

Additional Information

  • Source:Transfusion. 2023/10, Vol. 63, Issue S5, p10A
  • Document Type:Article
  • Subject Area:Psychology
  • Publication Date:2023
  • ISSN:0041-1132
  • DOI:10.1111/trf.1_17554
  • Accession Number:191023378
  • Copyright Statement:Copyright of Transfusion is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.